18F FDG positron-emission tomography findings of gliomatosis peritonei: A case report and review of the literature

Lavoie, Jean‐Michel; Lacroix-Poisson, F.; Hoang, Lynn; Wilson, Don; Seckl, Michael J.; Tinker, Anna V.

doi:10.1016/j.gore.2017.03.018

Cited by 10 publications

(12 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a result, the tumor was GP not recurrent IM. To date, only one report describes GP with FDG accumulation developed after treatment for IM (11). However, to our knowledge, this is the first report that describes GP with both FDG accumulation and contrast enhancement.…”

Section: Discussionmentioning

confidence: 88%

Gliomatosis peritonei with 18F-fluorodeoxyglucose accumulation and contrast enhancement secondary to immature teratoma: A case report

et al. 2018

View full text Add to dashboard Cite

Abstract. Gliomatosis peritonei (GP) is a rare condition characterized by mature glial tissue implants widespread in the peritoneum, which is occasionally followed by treatment for immature teratoma (IM). The present study reported a case of GP with fluorodeoxyglucose (FDG) accumulation and contrast enhancement followed by treatment for IM. A 30-year-old female, 2-gravida and 0-para, underwent laparotomy with hysterectomy, bilateral salpingo-oophorectomy, and partial omentectomy followed by four cycles of chemotherapy with bleomycin, etoposide, and cisplatin for IM (Grade 2) of stage IIIC. At the 6-month follow-up, computed tomography (CT) revealed a 1-cm mass with contrast enhancement on splenic flexure. Positron-emission tomography (PET)/CT revealed intense FDG accumulation at the same site. Although α-fetoprotein, which was elevated preoperatively, remained normal, she was diagnosed with IM recurrence. The patient underwent three cycles of chemotherapy with paclitaxel, ifosfamide, and cisplatin, but the size, the degree of contrast enhancement and FDG accumulation of the mass did not change after chemotherapy. A diagnostic laparoscopy was performed. which revealed multiple small peritoneal implants, including a 1-cm mass at the splenic flexure. The 1-cm mass was dissected at the splenic flexure and some other implants. Mature well-differentiated glial tissue with non-atypia was identified in all tissue, and a diagnosis of GP was made. The patient is currently undergoing regular follow-up. Few reports are available regarding FDG-PET/CT imaging of GP. GP should be considered as the differential diagnosis of FDG-avid mass followed by IM therapy. A laparoscopic diagnosis is useful to obtain an accurate diagnosis of GP.

show abstract

Section: Discussionmentioning

confidence: 88%

Gliomatosis peritonei with 18F-fluorodeoxyglucose accumulation and contrast enhancement secondary to immature teratoma: A case report

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Sin embargo, los implantes suelen ser muy pequeños (menores de 3 milímetros) y en ocasiones no pueden ser observados. Además, pueden estar ocultos por el gas intestinal o estar fuera del campo de visualización (9) . Los implantes pueden verse mejor con tomografía computarizada y resonancia magnética, pero no se puede establecer el origen exacto de estos implantes, ya que son similares a los observados en casos de carcinomatosis y tuberculosis peritoneal (10) .…”

Section: Discussionunclassified

“…Las imágenes ponderadas T2 proporcionan la mejor resolución, ya que los implantes tienen señal moderadamente alta. La tomografía con emisión de positrones puede ser también útil para el diagnóstico y monitoreo de las lesiones (9) . El diagnóstico definitivo de gliomatosis peritoneal se realiza por los hallazgos histológicos.…”

Section: Discussionunclassified

“…Hasta la fecha, no existen informes de casos de transformación maligna de la gliomatosis peritoneal asociada a teratoma quística maduro. Las pacientes con teratomas ováricos inmaduros e implantes gliales tienen mejor pronóstico si la superficie peritoneal, epiplón y superficies diafragmáticas tienen implantes compuestos, exclusiva o casi exclusivamente, de tejido glial maduro (9,15) . En conclusión, la gliomatosis peritoneal consiste en la presencia de implantes de tejido glial maduro en la superficie peritoneal.…”

Section: Discussionunclassified

See 1 more Smart Citation

Gliomatosis peritoneal asociada a teratoma maduro de ovario

Torres-Cepeda

Rondón-Tapía

2020

Rev peru ginecol obstet.

View full text Add to dashboard Cite

Los teratomas de ovario son tumores compuestos por tejidos derivados de las tres líneas germinales embrionarias. La gliomatosis peritoneal es una afección poco frecuente caracterizada por implantes de tejido glial en el peritoneo comúnmente asociada con teratoma inmaduro de ovario, no así con teratomas maduros. El diagnóstico definitivo se realiza por histología. No existen pautas sobre cómo realizar el seguimiento de los pacientes con esta afección. El pronóstico es favorable. Sin embargo, los implantes pueden experimentar regresión fibrótica o excepcionalmente degenerar a glioblastoma. Si están presentes tejido glial inmaduro u otros componentes teratomatosos en el peritoneo o epiplón, el tratamiento será similar al del carcinoma metastásico de ovario. En pacientes con enfermedad peritoneal residual, es necesario un seguimiento a largo plazo, debido al riesgo de recurrencia y transformación maligna. Se presenta un caso de gliomatosis peritoneal asociado a teratoma maduro de ovario.

show abstract

“…3,14 The diagnostic modality used for assessing residual masses after treatment for germ cell carcinoma, that is, FDG PET/CT is now widely available; this could be useful for the follow-up of GP. 15 However, as this condition is rare there is no widely accepted guidance as to how long and by which means these patients should be followed up. Our patient is on regular follow-up every six months.…”

Section: F I G U R Ementioning

confidence: 99%